{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:50:02Z","timestamp":1784605802552,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA251063"],"award-info":[{"award-number":["T32-CA251063"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12-CA076931-21"],"award-info":[{"award-number":["K12-CA076931-21"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA016520"],"award-info":[{"award-number":["P30-CA016520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA197916"],"award-info":[{"award-number":["R01-CA197916"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["PST-34-21"],"award-info":[{"award-number":["PST-34-21"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210730"],"award-info":[{"award-number":["W81XWH2210730"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"A Love for Life"},{"name":"Penn Pancreatic Cancer Research Center"},{"name":"Basser Center for BRCA"},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Konner Fund"},{"name":"Basser Center Young Leadership Award"},{"name":"Philip and Pearl Basser Award"},{"name":"anonymous foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy to treat, but emerging evidence suggests that specific subtypes may respond more favorably to certain therapies.\n                    <jats:italic>BRCA<\/jats:italic>\n                    -mutated PDAC represents a distinct subtype that is particularly sensitive to DNA-damaging therapies. The current standard of care for advanced\n                    <jats:italic>BRCA<\/jats:italic>\n                    -mutated PDAC involves induction platinum-based chemotherapy followed by maintenance therapy with a poly (ADP-ribose) polymerase inhibitor (PARPi). However, the randomized phase III POLO trial, upon which this standard is based, did not demonstrate an improved overall survival in patients who received olaparib compared to those who received placebo, highlighting the need for new therapeutic approaches. Additionally, there is a lack of robust models that recapitulate the tumor microenvironment of\n                    <jats:italic>BRCA<\/jats:italic>\n                    mutated PDAC, limiting the development of next-generation maintenance treatment options. In this study, we developed a syngeneic and immunocompetent mouse model of\n                    <jats:italic>Brca2<\/jats:italic>\n                    -mutated PDAC. The model demonstrated high sensitivity to cisplatin plus gemcitabine, but limited efficacy of PARPi monotherapy. Induction with platinum-based chemotherapy sensitized tumors to PARPi maintenance therapy and promoted an exhausted, T cell-inflamed tumor microenvironment. However, resistance emerged which was associated with CDX2 expression and tumor differentiation. The addition of anti-PD1 treatment to PARPi maintenance enhanced tumor regression and prolonged overall survival. These findings provide preclinical support for ongoing clinical trials investigating immunotherapy with PARPi as a maintenance strategy in homologous recombination-deficient PDAC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-35423-7","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:02:56Z","timestamp":1769835776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"John C.","family":"McVey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max M.","family":"Wattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Coho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayjana","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devora","family":"Delman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Clendenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma E.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Tondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Z.","family":"Stanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"35423_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"35423_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bjc.2017.19","volume":"116","author":"T Golan","year":"2017","unstructured":"Golan, T. et al. Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer. Br. J. Cancer. 116, 697\u2013702 (2017).","journal-title":"Br. J. Cancer"},{"key":"35423_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N Engl. J. Med."},{"key":"35423_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman, R. L. et al. Veliparib with First-Line chemotherapy and as maintenance therapy in ovarian cancer. N Engl. J. Med. 381, 2403\u20132415 (2019).","journal-title":"N Engl. J. Med."},{"key":"35423_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic Castration-Resistant prostate cancer. N Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N Engl. J. Med."},{"key":"35423_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg, M. M. et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br. J. Cancer. 122, 333\u2013339 (2020).","journal-title":"Br. J. Cancer"},{"key":"35423_CR7","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter, S. et al. Germline BRCA mutations in a large Clinic-Based cohort of patients with pancreatic adenocarcinoma. J. Clin. Oncol. 33, 3124\u20133129 (2015).","journal-title":"J. Clin. Oncol."},{"key":"35423_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s41416-021-01469-9","volume":"125","author":"E Lai","year":"2021","unstructured":"Lai, E. et al. BRCA-mutant pancreatic ductal adenocarcinoma. Br. J. Cancer. 125, 1321\u20131332 (2021).","journal-title":"Br. J. Cancer"},{"key":"35423_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance Olaparib for germline BRCA-Mutated metastatic pancreatic cancer. N Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N Engl. J. Med."},{"key":"35423_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.addr.2021.02.010","volume":"171","author":"T Golan","year":"2021","unstructured":"Golan, T., Atias, D., Stossel, C. & Raitses-Gurevich, M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv. Drug Deliv Rev. 171, 257\u2013265 (2021).","journal-title":"Adv. Drug Deliv Rev."},{"key":"35423_CR11","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","volume":"13","author":"C Stossel","year":"2023","unstructured":"Stossel, C. et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-Associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 13, 1826\u20131843 (2023).","journal-title":"Cancer Discov"},{"key":"35423_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"35423_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat. Cancer. 2, 66\u201382 (2021).","journal-title":"Nat. Cancer"},{"key":"35423_CR14","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnwald, B. T. et al., Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell (2021).","DOI":"10.1101\/2021.02.18.431890"},{"key":"35423_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 7, 469\u2013483 (2005).","journal-title":"Cancer Cell."},{"key":"35423_CR16","doi-asserted-by":"crossref","unstructured":"Li, J. et al., Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 2018;49:178\u2009\u2013\u200993.e7.","DOI":"10.1016\/j.immuni.2018.06.006"},{"key":"35423_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249\u2013252 (2019).","journal-title":"Nature"},{"key":"35423_CR18","doi-asserted-by":"publisher","first-page":"eadj5097","DOI":"10.1126\/sciimmunol.adj5097","volume":"8","author":"MM Wattenberg","year":"2023","unstructured":"Wattenberg, M. M. et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci. Immunol. 8, eadj5097 (2023).","journal-title":"Sci. Immunol."},{"key":"35423_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"35423_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495\u2013501 (2015).","journal-title":"Nature"},{"key":"35423_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"35423_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1101\/gad.348523.121","volume":"35","author":"GL Beatty","year":"2021","unstructured":"Beatty, G. L., Werba, G., Lyssiotis, C. A. & Simeone, D. M. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 35, 940\u2013962 (2021).","journal-title":"Genes Dev."},{"key":"35423_CR23","doi-asserted-by":"crossref","unstructured":"Garcia, G. L. et al., Aged and BRCA mutated stromal cells drive epithelial cell transformation. Cancer Discov (2025).","DOI":"10.1158\/2159-8290.c.7854034"},{"key":"35423_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41590-021-01120-y","volume":"23","author":"M Bruchard","year":"2022","unstructured":"Bruchard, M. et al. Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nat. Immunol. 23, 262\u2013274 (2022).","journal-title":"Nat. Immunol."},{"key":"35423_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).","journal-title":"Nat. Commun."},{"key":"35423_CR26","doi-asserted-by":"crossref","unstructured":"Farren, M. R. et al., Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight ;5 (2020).","DOI":"10.1172\/jci.insight.130362"},{"key":"35423_CR27","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/esmoopen-2020-000942","volume":"5","author":"A Seeber","year":"2020","unstructured":"Seeber, A. et al. Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 5, e000942 (2020).","journal-title":"ESMO Open."},{"key":"35423_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly, E. M. et al. Randomized, Multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J. Clin. Oncol. 38, 1378\u20131388 (2020).","journal-title":"J. Clin. Oncol."},{"key":"35423_CR29","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss, K. A. et al. Phase II study of maintenance Rucaparib in patients with Platinum-Sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J. Clin. Oncol. 39, 2497\u20132505 (2021).","journal-title":"J. Clin. Oncol."},{"key":"35423_CR30","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-23-1467","volume":"29","author":"TJ Brown","year":"2023","unstructured":"Brown, T. J. et al. The clinical implications of reversions in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on Rucaparib. Clin. Cancer Res. 29, 5207\u20135216 (2023).","journal-title":"Clin. Cancer Res."},{"key":"35423_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"35423_CR32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss, K. A. et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 23, 1009\u20131020 (2022).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35423-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:24:44Z","timestamp":1771413884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35423-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35423-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.M.W. reports prior or active roles as a consultant for Rondo Therapeutics and Nanology. B.Z.S. receives research funding from Boehringer-Ingelheim and Revolution Medicines and holds equity in iTeos Therapeutics. R.H.V has received consulting fees from BMS, EMD Serono, Grey Wolf Therapeutics and Crossbow Therapeutics, research funding form Revolution Medicines, is an inventor on patents relating to cancer cellular immunotherapy, cancer vaccines, and KRAS immune epitopes, and receives royalties form Children\u2019s Hospital Boston for a licensed research-only monoclonal antibody. G.L.B. reports active roles as consultant\/advisory board member for Hibercell, Pancreatic Cancer Action Network, EMD Serono and Alligator Biosciences; reports receiving active research funding from Alligator Biosciences, Incyte Corporation and Bristol-Myers Squibb; and is an inventor of intellectual property related to CAR T cells.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All data supporting the findings of this study are included in the paper and its Supplementary Information. RNAseq data have been deposited at the Gene Expression Omnibus (GEO) under accession numbers GSE300887 and GSE300888. Additional data are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data transparency"}}],"article-number":"6808"}}